Alliance For Clinical Trials In Oncology

This study looks at whether older adults with mantle cell lymphoma who achieve remission can safely stop taking zanubrutinib and restart it only if the cancer returns, instead of taking it every day indefinitely. The goal is to reduce side effects and costs without harming treatm…

This study tests whether giving chemotherapy and immunotherapy both before and after surgery is better than only after surgery for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 adults will be randomly assigned to one of the two approaches. …

This study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunothe…

This study tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 participants will receive either the standard two-drug treatment or the…

This study is for people with high-risk kidney cancer that has been removed by surgery. It compares the usual immunotherapy drug (pembrolizumab) alone versus the same drug plus a targeted therapy (tivozanib). The goal is to see if the combination works better at preventing the ca…

This study tests whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy helps young adults (ages 18-39) with newly diagnosed B-cell acute lymphoblastic leukemia. About 310 participants will receive either chemo alone or chemo plus the targeted drug. …

This study tests whether text messages can help rural cancer survivors who smoke to quit. About 600 participants will either get a text-based program that gradually reduces smoking or a self-help manual. The goal is to see which approach works better for long-term quitting.

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can help control a rare and aggressive type of mesothelioma called sarcomatoid mesothelioma. About 26 people with stage I to IIIa disease will receive the drugs, then undergo surgery…

This study looks at whether people with early-stage HER2-positive breast cancer who had a complete response to initial chemotherapy can safely stop targeted therapy after 6 months instead of the usual 12. About 1,500 participants will be randomly assigned to either 6 or 12 months…

This study tests four drugs (vismodegib, GSK2256098, capivasertib, abemaciclib) in 124 adults with progressive meningiomas that have certain gene mutations. The goal is to see if these targeted therapies can stop or slow tumor growth. Participants must have a confirmed meningioma…

This study is for people with colorectal cancer that has spread to up to 4 places in the body. It compares standard drug therapy alone versus standard therapy plus focused radiation, surgery, or heat-based tumor destruction. The goal is to see if adding these local treatments hel…

This study tests whether adding a new drug (iberdomide) to an existing treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has come back or stopped responding. About 88 adults with this blood cancer will receive either the new co…

This phase 3 trial tests whether adding the chemotherapy drug gemcitabine to standard BCG immunotherapy can better prevent bladder cancer from coming back. About 330 people with recurrent high-grade non-muscle invasive bladder cancer will receive either BCG alone or BCG plus gemc…

This study is for people with early-stage triple-negative breast cancer who had a complete response (no cancer left) after chemotherapy plus the immunotherapy drug pembrolizumab. The trial compares receiving more pembrolizumab versus simply being watched (observation) to see if t…

This study tests whether cancer patients can do a supervised exercise program at home using video calls. The goal is to prevent common side effects like fatigue and weakness. About 104 patients starting chemotherapy will take part. Researchers want to see if this approach is prac…

This study tests a new tool called the PAGODA algorithm to help doctors adjust chemotherapy doses proactively. The goal is to reduce unplanned treatment delays in people with gastrointestinal cancers receiving FOLFOX chemotherapy. About 420 participants will be randomly assigned …

This study tests if a high dose of gabapentin can help prevent the need for strong opioid painkillers in people with head and neck cancer who get mouth sores from chemotherapy and radiation. About 228 adults will be randomly assigned to receive gabapentin or a placebo during thei…

This study tests a vaginal laser treatment for breast cancer survivors who have vaginal dryness, often caused by cancer treatments like chemotherapy or hormone therapy. About 250 women who finished their main cancer treatment at least a year ago will receive either the laser or a…

This study collects blood, tissue, and health data from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. This will help scientists better understand, predict, and prevent …

This study compares a digital chatbot to standard remote genetic services for increasing genetic counseling and testing among young adults (ages 18-39) with cancer. The goal is to see if the chatbot makes it easier for patients to access recommended genetic testing, which can gui…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study tests whether analyzing the DNA and RNA of a patient's prostate cancer can help doctors pick the most effective treatment. About 474 men with advanced, treatment-resistant prostate cancer will have their tumor tissue tested for specific genetic changes. Based on the re…